Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04708860 · ClinicalTrials.gov registry record · NA
Feasibility of Fasting & Exercise in Pts With HR+ MBC
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04708860 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT04708860, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This research is evaluating the impact of a 12-week prolonged nightly fasting (POF) and exercise intervention on metabolic markers and patient reported outcomes in women with metastatic breast cancer (MBC) initiating endocrine therapy in combination with palbociclib or alpelisib.
Interventions
- BEHAVIORAL Exercise
- BEHAVIORAL Prolonged Nightly Fasting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2024-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04708860
The ClinicalTrials.gov registry entry for NCT04708860 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exercise is the first listed.
NCT04708860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04708860 about?
NCT04708860 is a clinical study titled "Feasibility of Fasting & Exercise in Pts With HR+ MBC". This research is evaluating the impact of a 12-week prolonged nightly fasting (POF) and exercise intervention on metabolic markers and patient reported outcomes in women with metastatic breast cancer (MBC) initiating endocrine therapy in combination with palbociclib or alpelisib.
What is the current status of trial NCT04708860?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-01-15. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT04708860?
The interventions under investigation include: Exercise (BEHAVIORAL), Prolonged Nightly Fasting (BEHAVIORAL).
Who is sponsoring clinical trial NCT04708860?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.